Among 10 patients with HCC who were evaluable for response and had known p53 mutational status, 86% (six of seven) of those with mutant p53 experienced a clinical benefit (two PRs and four SDs) compared with none of the patients with wild-type p53 tumors. The gene discussed is TP53; the disease is hepatocellular carcinoma.